iPS cells and research
Approvals and research news on iPS cell-derived products. In 2026 Japan granted its first conditional, time-limited approvals to iPS cell-derived products; here we follow what that does and does not mean.
01What this topic covers
- What iPS cells are
- Conditional, time-limited approval
- Post-marketing surveillance
- Research updates
02The first conditional approvals, 2026
On 6 March 2026 the MHLW granted conditional, time-limited (7-year) approval to Sumitomo Pharma’s iPS cell-derived product for Parkinson’s disease (アムシェプリ) and to Cuorips’ product for severe heart failure (リハート), the first iPS cell-derived products to be approved. After conditional approval, post-marketing surveillance of every treated case is still required before full approval can be applied for.
Conditionally approved products like these fall under insurance and are not the same thing as a clinic’s self-pay treatments.
Source: Science Portal (JST), 18 March 2026; Sumitomo Pharma announcement; Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11
03Guides in this topic
Guides are on the way
Guides for this topic are being prepared, each with its sources and the date it was checked. Meanwhile, start with these pages.